VentureBeat

Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies

Series A Financing led by EcoR1 Capital, Jeito Capital and Syncona with continued support of strategic seed investors Vida Ventures, TPG and Two River Neogene’s proprietary technology platform ...
Yahoo

AstraZeneca boosts cancer portfolio with $320 million Neogene deal

FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield (Reuters) -AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed ...
Nasdaq

Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies

Partnership Combines Twist’s Leadership in DNA Synthesis and Synthetic Biology with Neogene’s Expertise in Personalized Engineered T Cell Therapies “Engineered T cell therapies have demonstrated ...
Business Wire

Neogene Therapeutics Appoints Han Lee, Ph.D., MBA, as Chief Financial Officer

SANTA MONICA, Calif. & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a preclinical stage biotechnology company pioneering a new class of fully individualized T cell receptor (TCR) therapies ...
Nasdaq

AstraZeneca to buy Neogene for up to $320 mln in oncology push

Nov 29 (Reuters) - AstraZeneca AZN.L said on Tuesday it would acquire Neogene Therapeutics, a developer of cell-based cancer treatments, for up to $320 million, as the London-listed drugmaker seeks to ...
VentureBeat

Neogene Therapeutics Appoints Former Roche Chairman and Chief Executive Officer Franz B. Humer, Ph.D., as Executive Chairman of Board of Directors

Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced the appointment of ...
MM&M

AstraZeneca expands oncology portfolio with $320M deal for Neogene Therapeutics

AstraZeneca expanded its oncology portfolio Tuesday morning by announcing it reached an agreement to buy Neogene Therapeutics. The British pharma giant is purchasing the clinical-stage biotechnology ...
Digi Times

NeoGene unveils MagicWick-Inside platform for fabricating ultra-thin vapor chamber used in 5G smartphone thermal management applications

As demand for 5G mobile phones increases, the vapor chamber (VC) is emerging to become a key component in 5G smartphone thermal management. Competition is keen among vapor chamber suppliers, and there ...
FierceBiotech

Neogene adds ex-Roche director as CMO after snagging Bristol Myers, Arcellx vets

Raphaël Rousseau, M.D., Ph.D., is the latest biopharma vet to land at transatlantic biotech Neogene Therapeutics, where he joins a leadership bench of Kite and Bristol Myers Squibb veterans. Rousseau ...
The Business Journals

Neogene Therapeutics raises $110M to develop neo-antigen T cell therapies for cancer

Neogene aims to begin Phase I clinical studies in 2022. Neogene Therapeutics Inc. has raised $110 million in financing to advance the development of neo-antigen T cell therapies to treat various types ...
Business Wire

Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies

NEW YORK & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, ...